Speaker: Meletios Dimopoulos

0:01:37

Which is the best combination therapy in relapsed and refractory multiple myeloma?

0:01:32

The use of belantamab mafodotin in triplet combinations for multiple myeloma

0:00:43

The use of oral ixazomib maintenance following autoSCT in patients with NDMM

0:01:50

Which treatments are currently available for relapsed and refractory myeloma treatment?

0:01:50

STaMINA: Long-term follow-up

0:01:24

Disease characteristics of ultra-long-term multiple myeloma survivors

0:01:34

iNNOVATE study update: long-term PFS in WM

0:00:58

Patient-reported outcomes from the DREAMM-8 trial of belantamab mafodotin in multiple myeloma

0:01:06

Evolving strategies for second- and third-line treatments in multiple myeloma

0:01:56

Effective antibody therapy and updates from the POLLUX and CASTOR trials

0:01:23

Management of high-risk newly diagnosed MM

0:02:00

Updated results from DREAMM-8: belamaf plus pomalidomide and dexamethasone in R/R myeloma

0:01:58

The use of MRD to guide maintenance therapy discontinuation in patients with multiple myeloma

0:01:00

Dara-VRd in multiple myeloma with high-risk cytogenetics: insights from the PERSEUS trial

0:00:52

IMROZ trial updates: Isa-VRd versus VRd in patients with NDMM ineligible for transplant

0:01:42

First-in-human trial of an anti-BCMA ADC for R/R myeloma

0:01:29

Initial results of the phase III BOSTON study

0:00:51

Challenges in managing myeloma patients

0:00:58

Belantamab mafodotin: a potential new SoC in second-line myeloma based on the DREAMM trials

0:02:08

MagnetisMM-6 trial cohort G data: assessing EDR in transplant-ineligible newly diagnosed myeloma

0:01:28

The management of patients with myeloma who are anti-CD38 refractory

0:02:43

Imaging modalities and treatment breakthroughs in myeloma bone disease

0:01:19

Results of the PERSEUS trial: D-VRd with D-R maintenance in transplant-eligible newly diagnosed MM

0:01:19

Primary results of the AQUILA study: daratumumab versus active monitoring in high-risk SMM